| Revenue growth | H1 FY25 revenue ₹4,583 Lakh vs FY25 full year ₹8,417 Lakh. |
|---|---|
| Margins | EBITDA margin expanded to 18.75% in H1 FY25 from 15.58% in FY25. |
| Demand visibility | Strong domestic base with 50+ distributors and 12-country export presence. |
| Management confidence | High; citing 20+ years promoter expertise and robust R&D. |
Growth
H1 FY25 Revenue reached ₹4,718 Lakh with PAT of ₹548 Lakh. 3-year revenue CAGR stands at 32.16% (FY23-25).
Outlook
Targeting Rs 7.5 Lakh Cr Indian market by FY29; scaling HPC segment (14.21% of revenue currently); diversifying international presence.
Risks
Potential segment concentration in Textile; competitive specialty chemical landscape; environmental and regulatory compliance dependencies.
Earnings Call Transcript filed with NSE, NSE: NEOCHEM. Summary written with AI assistance from the document.
Neochem Bio Solutions Ltd: key numbers
- Share price
- ₹105.10
- Market cap
- ₹179.9 Cr
- Revenue (annual)
- ₹110.7 Cr
- Net profit (annual)
- ₹12.03 Cr
- P/E (TTM)
- 15.0×Sector 34.1×
- Promoter holding
- 66.88%
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neochem Bio Solutions Ltd
All →Neochem Bio Solutions Investor Presentation: Key Takeaways
H1 FY27 revenue ₹68.9 cr (+50% y-o-y), PAT ₹7.8 cr (+43%), but EBITDA margin fell to 18.0% from 21.7%. Strategy centres on diversification and bio-based chemistries.
Neochem Bio Solutions Management Change
Neochem Bio Solutions appointed Harshit Shah as CFO and Vikram Nair as CCO effective October 27. Solanki was redesigned from CFO to Senior VP Finance.
Neochem Bio Solutions H1 FY27 Results: Net Profit ₹7.8 Cr, Up 41.8% YoY
Neochem Bio Solutions Ltd reported revenue from operations of ₹68.9 Cr (+50.4% YoY) and net profit of ₹7.8 Cr (+41.8% YoY) for H1 FY27.
- Key figure
- Net profit ₹7.8 Cr · +41.8% YoY
Neochem Bio Solutions Other Announcement
Neochem Bio Solutions Limited submitted its Structured Digital Database (SDD) compliance certificate for the quarter and half-year ended September 30, 2026, as per SEBI regulations.
Neochem Bio Solutions Annual General Meeting
Neochem Bio Solutions Limited held its 9th Annual General Meeting on September 21, 2026, where management reviewed the company's performance and discussed future business strategies.
Neochem Bio Solutions Promoter Buying: ₹0.14 Cr
Promoter Swapnil R. Makati acquired 1,200 equity shares of Neochem Bio Solutions Limited for ₹0.14 Crore via an on-market purchase.
- Value
- ₹0.14 Cr
- Promoter stake change
- +0.01%